Injexate (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, disrupting folate metabolism. This inhibition reduces the production of nucleotides needed for DNA synthesis, thereby limiting the proliferation of rapidly dividing cells in the immune system and in malignant tumors.

The dosage of Injexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Only a qualified healthcare professional should determine the appropriate dose.

Methotrexate is generally contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug may be excreted in milk, so consultation with a specialist is essential.

To request Injexate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that is less expensive and can be administered subcutaneously. It has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for hepatic and hematologic toxicity.

Injexate should be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If refrigeration is unavailable for a short period, follow the manufacturer’s guidance on temperature excursions.

Injexate is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation. Administration is performed by a healthcare professional or a trained patient following aseptic technique and proper disposal of sharps.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to infections or bleeding, and rare but life‑threatening skin reactions. Regular monitoring of liver enzymes, lung function, and blood counts helps detect these complications early.

Patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, or those who are pregnant should not use Injexate. Additionally, individuals receiving live vaccines or certain interacting medications should avoid or use the drug only under strict medical supervision.